BioPharma💊 DTx📲 Strategic Advisor|Consultant
COMMERCIALIZATION • GTM • GROWTH:
• Market Access & Reimbursement
• Value Strategy & Payer Engagement
• Real World Evidence & Outcomes
• Pricing & Contracting
• Sales & Business Development
PRIOR:
🍐Pear Therapeutics 🇫🇷Sanofi 🇺🇸Allergan 🇩🇪Merck KGaA 🇮🇪ICON plc 🇺🇸IQVIA / Beansprout Networks
Some HEALTH TECH START UP LEADERSHIP / ADVISOR examples:
#1 - B2B2C Pediatric Channel Services ($35M raised, acquired by Quintiles/IQVIA ‘02) - Head of Business & Network Development
#2 - Big Data, Longitudinal Health Record
($86M raised thru Series C) - Chief Commercial Advisor
#3 - Digital Health, Medication Adherence ($51.5M, raised thru Series C) - Outcomes based Business Model Consultant
#4 - Rx Digital Therapeutics ($234M raised thru Series D / driver of $1.6B enterprise value preceding SPAC merger) - Global Head of Market Access, Value & Evidence
#5 - DTx stealth start up (Middle East, seed) - Advisor
#6 - DTx/PDT 🇺🇸 start up ($171M raised through Series C)
HOW I SHARE AND CONTRIBUTE:
📈 Interim Management • Adviser • Strategic Consulting • Outside Board Member
🖇 Founder & CEO 🌴PALMHealth.co
🖋 Mentor, Volunteer, Writer, Collaborator
LINKED IN:
http://linkedin.com/in/michael-pace-dtx-vba-maven
Invited by: Mark Czubachowski
if the data has not been changed, no new rows will appear.
Day | Followers | Gain | % Gain |
---|---|---|---|
October 12, 2023 | 109 | +6 | +5.9% |
October 23, 2022 | 103 | -1 | -1.0% |
August 22, 2022 | 104 | +2 | +2.0% |
July 16, 2022 | 102 | +1 | +1.0% |
May 02, 2022 | 101 | +1 | +1.0% |
March 25, 2022 | 100 | +2 | +2.1% |
November 12, 2021 | 98 | +2 | +2.1% |
October 04, 2021 | 96 | +1 | +1.1% |
August 20, 2021 | 95 | +7 | +8.0% |